Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05941299
Other study ID # Tens-BBC/003/2021
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 29, 2023
Est. completion date December 30, 2029

Study information

Verified date February 2024
Source Tensive SRL
Contact Margherita Tamplenizza
Phone +39 0256660185
Email margherita.tamplenizza@tensivemed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goals of this clinical trial are: - demonstrate the safety of REGENERA breast implant in patients undergoing lumpectomy of malignant breast lesions - demonstrate the safety and performance of REGENERA in terms of investigator's satisfaction, potential interference with current standard-of-care imaging techniques and occurrence of device-related serious adverse events. Participants will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan: - Screening - Pre-surgery treatment - Surgery and study device implant - Post-surgery follow-up up to 5 years


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date December 30, 2029
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Female adult subject aged 40-70 years. - Subject diagnosed with malignant breast lesion: - monolateral nodular infiltrative carcinoma, - without microcalcification, - single or multifocal, - included in an area with a maximum diameter of 4 cm, - non-metastatic (M0). - Subject with clinically negative axilla. - Subject considered eligible for conservative breast surgery - BCS (Breast-Conserving Surgery, lumpectomy or quadrantectomy), leaving a volume deficit compatible with a REGENERA implant (available in two dried sizes) volume of 70 ml or 100 ml. - Confirmation of malignant lesion (pT1, pT2, pN0, pN1) with no discordance between biopsy and radiological imaging. - Adequate hematopoietic functions. - Good general health and mentally sound. - Subject able and willing to give written informed consent form. Exclusion Criteria: - Subject with actual concomitant benign breast lesion (B2 and B3), unless present in the same mammary quadrant or in the contralateral breast. - Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease. - Axillary dissection planned as part of the breast lesion surgery. - History of surgery, chemotherapy, neoadjuvant chemotherapy, or irradiation of the breast parenchyma object of the study. - Skin retraction at the breast to be operated. - Infection of the surgical site confirmed pre-operatively by clinical examination. - Abnormal blood sugar and glycosylated hemoglobin. - Hard smoker (more than 10 cigarettes a day). - Acute or chronic severe renal insufficiency (creatinine values >180 µmol/l). - History of severe asthma or allergies (including allergy to anesthetics or contrast media). - Autoimmune disease. - Subjects who are known to be carriers of BCRA mutation. - Inability to undergo MRI or allergy to contrast media. - Systemic infections in an active phase. - Immunocompromised patients (HIV). - Pregnant or breastfeeding woman or woman who has nursed a child within 3 months prior to enrolment in the study. - Subject who has participated in another interventional study within the past 3 months. - Subject who received immunosuppressant therapy in the last 3 months. - History of substance abuse (drug or alcohol). - Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).

Study Design


Intervention

Device:
REGENERA breast implant implantation
Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan: Screening Pre-surgery treatment Surgery and study device implant Post-surgery follow-up

Locations

Country Name City State
Italy IEO Istituto Europeo di Oncologia Milan
Italy A.O.U. Pisana - Ospedale Santa Chiara Pisa
Spain Complejo Hospitalario Universitario A Coruña A Coruña

Sponsors (1)

Lead Sponsor Collaborator
Tensive SRL

Countries where clinical trial is conducted

Italy,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of adverse events (AEs) with a causal relationship to REGENERA at 3 months. The rate of AEs with a causal relationship to REGENERA should be <5% at 3 months after implant. 3 months
Secondary Mean investigator's satisfaction on the implanting procedure at 1week. At least 7 in a 0-10 Visual Analogue Scale, VAS. 1 week after implant
Secondary Mean investigator's satisfaction on REGENERA usability during surgery at 1 week. At least 40 in an "ad hoc" questionnaire (12-60 scale). 1 week after implant
Secondary Mean investigator's satisfaction on overall surgical procedure and clinical outcome of the patient at 12 months. At least 7 in a 0-10 Visual Analogue Scale, VAS. 12 months
Secondary Number of interference events of REGENERA with ultrasound imaging technique, through the completion of a questionnaire by the investigators. An imaging evaluation questionnaire will be provided for investigators to fill out. After 6 and 12 months
Secondary Number of interference events of REGENERA with mammography imaging technique, through the completion of a questionnaire by the investigators. An imaging evaluation questionnaire will be provided for investigators to fill out. After 12 months
Secondary Number of interference events of REGENERA with MRI (with and without contrast) imaging technique, through the completion of a questionnaire by the investigators. An imaging evaluation questionnaire will be provided for investigators to fill out. After 6 and 18 months
Secondary Rate of serious adverse events (SAEs) with a causal relationship to REGENERA after 3 months and up to 18 months. The rate of REGENERA-related SAEs should be <5% at each follow-up after 3 months and up to 18 months. After 3 months and up to 18 months
Secondary Rate of SAEs with a causal relationship to REGENERA after 18 months and up to 5 years. The rate of REGENERA-related SAEs should be <7% at each follow-up after 18 months and up to 5 years. After 18 months and up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT04348955 - Interest of Touch-massage in Hospital Day Care
Completed NCT05812326 - PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT04424732 - SBRT for Breast Cancer Oligometastases N/A
Completed NCT03109080 - Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) Phase 1
Recruiting NCT04198727 - Study of the Impact of DPD Activity on the Efficacy of Capecitabine N/A
Completed NCT03525990 - Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients N/A
Recruiting NCT04289805 - Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) Phase 4
Available NCT05134922 - Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009